HMH Maestro

Leadership Announcements

Andre Goy, M.D., Appointed Physician-in-Chief to Lead Cancer Care Across HMH

Oncology

What you need to know

Andre Goy, M.D., M.S., has been appointed as physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service.

In this role, he oversees the delivery of cancer care across the entire Hackensack Meridian Health network, the largest cancer program in New Jersey.

Dr. Goy has been chairman and executive director of John Theurer Cancer Center at Hackensack University Medical Center since 2011 and chair of oncology for Hackensack Meridian Health since 2016. He is also professor of medicine at Georgetown University and professor and chair of oncology at Seton Hall–Hackensack Meridian School of Medicine. Under his leadership, John Theurer Cancer Center became a member of the Georgetown Lombardi Comprehensive Cancer Center Consortium — one of only 16 research consortia in the nation approved by the National Cancer Institute.

As chief of the Division of Lymphoma since 2005 and holder of the Lydia Pfund Chair for Lymphoma since 2017, he has led New Jersey’s largest program focused on the research and treatment of all types of lymphoma — including Hodgkin disease, non-Hodgkin lymphoma, mantle cell lymphoma, and HIV-associated lymphoma. An internationally renowned lymphoma clinician and researcher,      Dr. Goy has trained and/or worked at leading medical institutions, including Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, University Hospitals Group of Paris, and The Pasteur Institute in Paris.

Research

Dr. Goy is widely known for his work on novel therapies for mantle cell lymphoma, having been principal investigator or co-investigator of the studies behind all four drugs approved to treat mantle cell lymphoma. He first showed evidence of activity of the drug bortezomib in recurrent or persistent mantle cell lymphoma, and then led the pivotal trial of lenalidomide for this disease while participating in the development of both BTK inhibitors ibrutinib and acalabrutinib. These novel agents are transforming the treatment of this disease, which often becomes resistant to standard therapy and has a very poor outcome.

Dr. Goy also initiated CAR T-cell therapy at John Theurer Cancer Center, in collaboration with the team of Steve Rosenberg at the National Cancer Institute. CAR T cell is a form of cellular therapy where a patient’s own immune cells are genetically engineered to force them to attack cancer cells. CAR  T cells became the first live therapy approved in 2017 for aggressive lymphoma and leukemia. It is recognized as a revolutionary treatment that is now being expanded to the treatment of other lymphomas, multiple myeloma, and hopefully soon for solid tumors. 

Publications

He has published extensively and serves as reviewer for many prestigious journals, including New England Journal of Medicine, Journal of Clinical Oncology, Blood, and others. He has co-chaired the Global Council on the Future of Health and Healthcare for the World Economic Forum. Dr. Goy believes that the world is at an inflection point in medicine due exponential and converging advances in science, discovery, and technologies, including artificial intelligence and augmented reality, which will help reshape health monitoring and totally transform care delivery. He has been invited to speak and teach across the globe.